Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "new"

5221 News Found

Kindeva appoints David Stevens as new CEO
People | January 20, 2026

Kindeva appoints David Stevens as new CEO

Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors


Alto Neuroscience bags new US patent for depression drug ALTO-207
News | January 20, 2026

Alto Neuroscience bags new US patent for depression drug ALTO-207

ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease


Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet
News | January 16, 2026

Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet

The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign


Merck scores FDA nod for TGT drug Pimicotinib, promising new hope for patients
Drug Approval | January 14, 2026

Merck scores FDA nod for TGT drug Pimicotinib, promising new hope for patients

The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes


GEA to power new biotechnology fermentation hub in Netherlands
Biotech | January 14, 2026

GEA to power new biotechnology fermentation hub in Netherlands

BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities


AstraZeneca appoints Laura Colon as new President of Spain
People | January 10, 2026

AstraZeneca appoints Laura Colon as new President of Spain

After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets


Newron secures key European patent for schizophrenia drug Evenamide
Biopharma | January 09, 2026

Newron secures key European patent for schizophrenia drug Evenamide

This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately


Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity
News | January 08, 2026

Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity

The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies


FDA nod to first new motion sickness drug in 40 years
Clinical Trials | January 04, 2026

FDA nod to first new motion sickness drug in 40 years

The approval is supported by data from three pivotal clinical trials


Elanco scores USDA nod for new canine allergy drug Befrena
News | January 04, 2026

Elanco scores USDA nod for new canine allergy drug Befrena

Elanco expects Befrena to launch in the US in the first half of 2026